GoAI
Get started
Vericel Corporation logo

Vericel Corporation

VCEL

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$42.68

+$0.57 · +1.35%

Aug 21, 4:00 PM ET

VCEL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

62

Undervalued

Momentum

67

Gaining

Sentiment

66

Bullish

Risk resilience

67

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Dominick C. Colangelo
Listed since
Feb 4, 1997
Employees
398

Market position

Day range

Current $42.68

52-week range

Current $42.68

Open
$42.34
Previous close
$42.11
Volume
647.13K
1.09× average
Average volume
594.47K
Average daily volume
Market cap
2.19B USD
Beta
1.07
Market reference 1
50-day average
$44.4088
-3.89% below average
200-day average
$38.0476
+12.18% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.82B USD
P/E (TTM)
88.92×
P/B (TTM)
5.87×
P/S (TTM)
7.14×
EV / EBITDA
60.08×
Earnings yield
0.91%
Free cash flow yield
1.36%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
74.56%
Operating margin
5.95%
Net margin
7.91%
Return on equity
4.66%
Return on assets
3.39%
Return on invested capital
2.32%

Financial health

Debt / equity
0.25×
Current ratio
5.03×
Altman Z-score
10.1
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends83%49%15%-19%Gross margin, FY2021: 67.88%Gross margin, FY2022: 66.80%Gross margin, FY2023: 68.64%Gross margin, FY2024: 72.55%Gross margin, FY2025: 74.42%Operating margin, FY2021: -5.03%Operating margin, FY2022: -10.38%Operating margin, FY2023: -3.27%Operating margin, FY2024: 1.90%Operating margin, FY2025: 4.00%Net margin, FY2021: -4.78%Net margin, FY2022: -10.17%Net margin, FY2023: -1.61%Net margin, FY2024: 4.37%Net margin, FY2025: 5.98%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 67.88%. Gross margin FY2022 66.80%. Gross margin FY2023 68.64%. Gross margin FY2024 72.55%. Gross margin FY2025 74.42%. Operating margin FY2021 -5.03%. Operating margin FY2022 -10.38%. Operating margin FY2023 -3.27%. Operating margin FY2024 1.90%. Operating margin FY2025 4.00%. Net margin FY2021 -4.78%. Net margin FY2022 -10.17%. Net margin FY2023 -1.61%. Net margin FY2024 4.37%. Net margin FY2025 5.98%.

Income trends

Revenue

276.26M USD+16.45%

Operating income

11.04M USD+144.39%

Net income

16.52M USD+59.41%
Income trends across reported periods305.59M USD188.26M USD70.94M USD−46.39M USDRevenue, FY2021: 156.18M USDRevenue, FY2022: 164.37M USDRevenue, FY2023: 197.52M USDRevenue, FY2024: 237.22M USDRevenue, FY2025: 276.26M USDOperating income, FY2021: −7.85M USDOperating income, FY2022: −17.06M USDOperating income, FY2023: −6.46M USDOperating income, FY2024: 4.52M USDOperating income, FY2025: 11.04M USDNet income, FY2021: −7.47M USDNet income, FY2022: −16.71M USDNet income, FY2023: −3.18M USDNet income, FY2024: 10.36M USDNet income, FY2025: 16.52M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 156.18M USD. Revenue FY2022 164.37M USD. Revenue FY2023 197.52M USD. Revenue FY2024 237.22M USD. Revenue FY2025 276.26M USD. Operating income FY2021 −7.85M USD. Operating income FY2022 −17.06M USD. Operating income FY2023 −6.46M USD. Operating income FY2024 4.52M USD. Operating income FY2025 11.04M USD. Net income FY2021 −7.47M USD. Net income FY2022 −16.71M USD. Net income FY2023 −3.18M USD. Net income FY2024 10.36M USD. Net income FY2025 16.52M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue276.26M USD237.22M USD197.52M USD164.37M USD156.18M USD
Cost of goods sold70.66M USD65.12M USD61.94M USD54.58M USD50.16M USD
Gross profit205.6M USD172.11M USD135.58M USD109.79M USD106.03M USD
Research and development27.56M USD24.8M USD21.04M USD19.94M USD16.29M USD
Selling, general, and administrative166.99M USD142.79M USD121M USD106.9M USD97.59M USD
Operating expenses194.56M USD167.59M USD142.04M USD126.85M USD113.88M USD
Interest income7.01M USD6.41M USD4.63M USD1.34M USD224K USD
Interest expense1.56M USD614K USD600K USD366K USD4K USD
Depreciation and amortization11.36M USD5.5M USD4.63M USD3.98M USD2.97M USD
Operating income11.04M USD4.52M USD−6.46M USD−17.06M USD−7.85M USD
Net income16.52M USD10.36M USD−3.18M USD−16.71M USD−7.47M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 1 miss, 2 met estimates
Average EPS surprise
+85.50%
11 comparable reports
Latest EPS result
0.04
Estimate -0.03 · Beat by 238.22%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.50.24-0.02-0.28Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MetQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 0.38, estimate 0.31, surprise +22.58%, Beat. Q2 2025, reported May 8, 2025: actual -0.23, estimate -0.09, surprise -155.56%, Miss. Q3 2025, reported Jul 31, 2025: actual -0.01, estimate -0.04, surprise +75.00%, Beat. Q4 2025, reported Nov 6, 2025: actual 0.1, estimate -0.02, surprise +600.00%, Beat. Q1 2026, reported Feb 26, 2026: actual 0.45, estimate 0.45, surprise 0.00%, Met estimate. Q2 2026, reported May 7, 2026: actual -0.12, estimate -0.15, surprise +20.00%, Beat. Q3 2026, reported Jul 30, 2026: actual 0.04, estimate -0.029, surprise +238.22%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 0.02, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates96.63M80.72M64.8M48.88MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 75.38M USD, estimate 58.12M USD, surprise +29.69%, Beat. Q2 2025, reported May 8, 2025: actual 52.6M USD, estimate 64.81M USD, surprise -18.84%, Miss. Q3 2025, reported Jul 31, 2025: actual 63.24M USD, estimate 64.57M USD, surprise -2.06%, Miss. Q4 2025, reported Nov 6, 2025: actual 67.5M USD, estimate 92.66M USD, surprise -27.15%, Miss. Q1 2026, reported Feb 26, 2026: actual 92.92M USD, estimate 90.97M USD, surprise +2.14%, Beat. Q2 2026, reported May 7, 2026: actual 68.43M USD, estimate 63.68M USD, surprise +7.46%, Beat. Q3 2026, reported Jul 30, 2026: actual 77.46M USD, estimate 72.7M USD, surprise +6.54%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 77.98M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$57.50

34.72% upside
Past 12 months12-month forecastHigh $70.00Average $57.50Low $46.00

Rating distribution

14 ratings
Strong buy00%
Buy964%
Hold536%
Sell00%
Strong sell00%

Recent analyst actions

6 institutions

VCEL news

defenseworld.net

Vericel Corporation $VCEL Shares Purchased by Bank of America Corp DE

Bank of America Corp DE boosted its holdings in Vericel Corporation (NASDAQ: VCEL) by 19.7% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 1,098,771 shares of the…

Read source
marketbeat.com

Vericel Q2 Earnings Call Highlights

Vericel NASDAQ: VCEL reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and…

Read source
seekingalpha.com

Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript

Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript

Read source
zacks.com

Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates

Vericel Corporation (VCEL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago.

Read source
globenewswire.com

Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program

Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of…

Read source
defenseworld.net

Vericel Corporation $VCEL Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC trimmed its position in Vericel Corporation (NASDAQ: VCEL) by 3.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The…

Read source

Corporate actions

Corporate action history

Stock split

Effective Oct 16, 2013

1:20

Stock split

Effective Feb 18, 2010

1:8

VCEL peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding VCEL

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
135.38M
Weight
0.12%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31—
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
74.7M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24—
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
55.46M
Weight
0.07%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96—
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
52.79M
Weight
0.46%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73—
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
27.1M
Weight
0.03%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53—
iShares S&P Small-Cap 600 Growth ETF logoiShares S&P Small-Cap 600 Growth ETFIJT
Market value
20.61M
Weight
0.24%
AUM
8.22B USD
Expense ratio
0.18%
Price / 1D
$173.9—
State Street SPDR Portfolio S&P 600 Small Cap ETF logoState Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Market value
20.21M
Weight
0.12%
AUM
17.03B USD
Expense ratio
0.03%
Price / 1D
$57.28—
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
20.04M
Weight
0.13%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37—

Continue in GoAI

Research VCEL

research.disclaimer